Deutsche Bank raised the firm’s price target on Praxis Precision (PRAX) to $280 from $65 and keeps a Buy rating on the shares. The company reported a “surprise win” for ulixacaltamide in essential tremor, the analyst tells investors in a research note. The firm remains a buyer of the stock after yesterday’s big rally on its potential in epilepsy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision price target raised to $330 from $80 at Chardan
- Why This Biotech Stock Exploded 184% to a Three-Year High
- Closing Bell Movers: CSX gains over 2% on earnings beat; OZK slips on miss
- Praxis Precision $400M Spot Secondary; price range $152.00-$157.00
- Praxis $400M share sale said to be priced between $152-$157, Bloomberg says